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Introduction
Polymyositis (Pm) and dermatomyositis (Dm) are autoim-
mune muscle disorders that symmetrically affect primar-
ily the proximal limbs, neck, and pharyngeal muscles. Dm 
is accompanied by a characteristic rash such as Gottron’s 
papules and heliotrope rash of the eyelids. CD4+ t cells, 
CD8+ t cells, macrophages, and dendritic cells infiltrate 
around muscular tissue and blood vessels with degen-
eration and regeneration of muscular fibers. Inflammatory 
cytokines such as tnF-α, IL-1, IL-6, IL-15, and IL-18 
are thought to play a crucial role in the pathogenesis of 
Pm/Dm [1].
type I interferon (IFn) is a giant cytokine family 
including IFn-α, IFn-β, IFn-ω, IFn-λ, and IFn-τ. these 
cytokines have antiviral and antitumor activities. IFn-
α and IFn-β are used to treat viral hepatitis or malignant 
melanoma. Furthermore, the efficacy of IFn-β for multi-
ple sclerosis was also demonstrated [2]. however, several 
studies reported that autoimmune diseases such as systemic 
lupus erythematosus and Pm/Dm can develop during treat-
ment with IFn-α or IFn-β [3–14]. We report a patient who 
developed Dm as a complication of IFn-α therapy for 
hepatitis C. In this patient, dermatomyositis was rapidly 
progressive and successfully treated with glucocorticoid 
therapy in addition to intravenous immunoglobulin (IVIG) 
and tacrolimus without reactivation of the hepatitis C virus.
Case report
a 52-year-old man was diagnosed as being a hepatitis C 
virus (hCV, Genotype 1) carrier in 1997, but he was not 
treated. he sought medical advice in regard to hepatitis at 
a hospital. Combination therapy with weekly subcutaneous 
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injection of pegylated IFn-α-2b (PEG-IFn-α-2b) 100 mg/
body and oral administration of ribavirin 800 mg/day were 
initiated in June 2011. Erythema involving the cervical 
and dorsal regions appeared, and weight loss was noted 
3 months after the initiation of therapy. In January 2012, 
exacerbation of the erythema, general malaise, muscular 
pain, and a severe increase in the level of creatine kinase 
(CK) 23–36,500 u/l were observed. therefore, PEG-
IFn-α-2b and ribavirin were discontinued, and the patient 
was admitted to our hospital. heliotrope rash on the eye-
lids, shawl sign, and protruding and purple-red erythema 
(Fig. 1) were present on the posterior cervical to dorsal 
and anterior cervical to thoracic regions. Proximal upper 
limb-dominant muscular weakness of the cervical flexors 
and deltoid muscle and decreased grip strength were also 
observed. the blood examination showed increased levels 
of CK (29,333 u/l), aldolase (288.8 u/l), C-reactive pro-
tein (3.94 mg/dl), aspartate aminotransferase (1,106 u/l), 
alanine aminotransferase (1,171 u/l), and lactate dehy-
drogenase (1,709 u/l). the thyroid function was normal. 
Positive levels of antinuclear antibody (1:640, speck-
led pattern) were detected. anti-aminoacyl tRna syn-
thetase (aRS), anti-signal recognition particle, anti-mi-2 
antibody, anti-Pm/SCL antibody, anti-mDa5 antibody, 
Fig. 1  a Erythema on the 
posterior cervical region. b, c 
monocytes and lymphocytes 
infiltrate around blood vessels 
in the superficial corium layer 
and in the middle to deep layers 
of the corium. (b h&E, ×40) (c 
h&E, ×400) d and e Lympho-
cytes stained with CD4 infiltrate 
into the perivascular region 
more than those with CD8. 
(d immunostaining for CD4, 
×400) (e immunostaining for 
CD8, ×400)
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anti-ribonucleoprotein antibody, anti-double stranded 
Dna antibody, and other disease-specific autoantibodies 
were negative. Complement level was normal. Electro-
myography showed proximal muscle-predominant myo-
genic changes. magnetic resonance imaging of upper limbs 
showed diffuse myopathy. a skin biopsy showed infil-
tration of monocytes and CD4+-dominant lymphocytes 
around blood vessels in the superficial corium layer and in 
the middle to deep layers of the corium (Fig. 1). although 
a muscle biopsy was not performed because of the patient’s 
non-consent, based on these findings, a diagnosis of Dm 
was made [3, 4], and prednisolone 80 mg/day and IVIG 
(400 mg/kg/day × 5 days) were initiated. Because a suf-
ficient decrease in the levels of muscle enzymes was not 
achieved, administration of tacrolimus (3 mg/day) was ini-
tiated 13 days after admission, and IVIG was performed 
twice more. the serum levels of muscle enzymes decreased 
to the reference range without the reactivation of hCV.
Discussion
We experienced a patient who developed Dm during IFn-
α therapy for hepatitis C. Eleven patients with Pm/Dm 
(8 with Pm and 3 with Dm) related to IFn-α therapy, 
including our patient, have been reported (table 1) [5–14]. 
Pm/Dm related to IFn-α therapy is more frequent in males. 
the diseases for which IFn-α therapy was indicated in 
these patients included hepatitis C in 6 patients, malignant 
melanoma in 2, hepatitis B in 1, essential thrombocytosis 
in 1, and chronic myelocytic leukemia in 1. most patients, 
including our patient, developed Pm/Dm within 3 months 
after the start of IFn-α therapy that ranged from 2 weeks 
to 7 months in duration. two previously reported patients 
with Dm were positive for anti-aRS antibodies, such as 
anti-Jo-1 and anti-PL-7 antibodies, and interstitial pneu-
monia was concomitantly present [5, 6]. however, these 
findings were absent in our patient. the Pm/Dm related to 
IFn-α in these patients responded to treatment well with a 
favorable prognosis. In one patient, the discontinuation of 
IFn-α improved Dm spontaneously without immunosup-
pressive treatment.
Re-administration of IFn-α should be considered cau-
tiously. It was reported that re-administration of IFn-α 
caused rapid recurrence of myositis in a patient with inclu-
sion body myositis related to IFn-α [17]. however, the dis-
continuation of IFn therapy in hCV carriers or the use of 
steroids in hCV-infected patients may increase the Rna 
levels of hCV, causing hepatitis [18]. We could find no 
reports of reactivation of hCV or onset of hepatitis caused 
by discontinuation of IFn-α or start of immunosuppressive 
therapy in IFn-α-related Dm/Pm patients with hCV infec-
tion. Reactivation of hCV in our patient was not observed 
despite strong immunosuppressive therapy with high-dose 
glucocorticoid and tacrolimus. however, therapeutic strate-
gies for the reactivation of hCV or progression of hepatitis 
are not established, and care must be taken to avoid these 
risks.
Table 1  Dm and Pm associated with IFn alpha therapy
Ref reference, DM dermatomyositis, PM polymyositis, M male, F female, PEG pegylated, IFN interferon, Ab antibodies, ANA anti-nuclear anti-
bodies, PDN prednisolone, MPDN methylprednisolone, DEX dexamethasone, MTX methotrexate, TAC tacrolimus, IVIG intravenous immuno-
globlin, ND not described, IP interstitial pneumonia
Ref Dm or Pm age/sex Disease IFn Latency autoantibodies IP treatment Outcome
[3] Dm 62/F hepatitis C PEG-IFn-α-2b 2 weeks anti-PL-7 ab, ana + PDn, IVIG Improved
[4] Dm 57/F malignant melanoma IFn-α 6 weeks anti-Jo-1 ab + DEX, mtX Improved
[5] Pm 50/F hepatitis C PEG-IFn-α 2 months none nD PDn Improved




[7] Pm 47/m hepatitis C IFn-α 2 months ana nD PDn, steroid pulse Improved
[8] Pm 51/m hepatitis C IFn-α-2b 6 months nD nD nD Improved
[9] Pm 33/m hepatitis B IFn-α 6 weeks none nD PDn, IVIG Improved
[10] Pm 50/F Essential thrombocy-
tosis
IFn-α-2b 2 months none nD PDn, IVIG Improved
[11] Pm 48/F malignant melanoma IFn-α 7 months anti-thyroglobulin 
ab, anti- 
peroxidase ab
nD PDn, steroid pulse Improved
[12] Pm 24/m Chronic myeloid 
leukemia
IFn-α nD none nD mPDn Improved
Ours Dm 52/m hepatitis C PEG-IFn-α-2b 3 months ana – PDn, IVIG, taC Improved
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type I IFn is involved in the pathogenesis of autoim-
mune diseases such as systemic lupus erythematosus and 
Pm/Dm [19–21]. a large number of plasmacytoid den-
dritic cells infiltrate into the muscle tissue of patients with 
Pm/Dm, and mRnas of the type I IFn-associated gene 
(IFn signature) are highly expressed [22]. myxovirus-
resistant protein a, a gene that is induced by type I IFn, is 
highly expressed in the muscle fibers and blood vessels of 
these patients [22, 23]. Pm/Dm as a complication of IFn-
α, including that in the present patient, indicates that type 
I IFn may be involved in the onset of Pm/Dm, although 
the exact relation between type I IFn and the development 
of Pm/Dm as well as the potential mechanism of disease 
development remain unclear. these issues must be exam-
ined more thoroughly in the future.
We presented a patient who developed Dm during the 
administration of IFn-α for treatment of hepatitis C. he 
was successfully treated with IVIG and tacrolimus in addi-
tion to glucocorticoid despite serious muscular symptoms. 
Several similar cases of Pm/Dm as a complication related 
to IFn-α have been reported. these cases suggest that IFn-
α may contribute to the pathogenesis of Pm/Dm.
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